Join Us | Latest Articles | Contact

Journal Home


Editorial Board


Recent Articles


Submit to this journal


Special Issues


Current issue

International Journal of Cancer and Clinical Research





DOI: 10.23937/2378-3419/2/3/1019



Screening for the Polyomaviruses BKV, JCV and SV40 in Pediatric Malignancies

Karin Kosulin1#, Alexander Zimmerhackl1#, Johannes A. Hainfellner2, Christine Haberler2, Gabriele Amann3, Susanna Lang3 and Thomas Lion1,4*


1Children's Cancer Research Institute, Austria
2Institute of Neurology, Medical University of Vienna, Austria
3Department of Clinical Pathology, Medical University of Vienna, Austria
4Department of Pediatrics, Medical University of Vienna, Austria
#Equal Contribution


*Corresponding author: Thomas Lion, St. Anna Kinderkrebsforschung, Children's Cancer Research Institute, Zimmermannplatz 10, A-1090 Vienna, Austria, Tel: +43-(0)1-40077-4890, Fax: +43-(0)1-40077-64890, E-mail: Thomas.Lion@ccri.at
Int J Cancer Clin Res, IJCCR-2-019, (Volume 2, Issue 3), Research Article; ISSN: 2378-3419
Received: June 11, 2015 | Accepted: July 29, 2015 | Published: July 31, 2015
Citation: Kosulin K, Zimmerhackl A, Hainfellner JA, Haberler C, Amann G, et al. (2015) Screening for the Polyomaviruses BKV, JCV and SV40 in Pediatric Malignancies. Int J Cancer Clin Res 2:019. 10.23937/2378-3419/2/3/1019
Copyright: © 2015 Kosulin K, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.



Abstract

Different studies suggested an oncogenic potential of the polyomaviruses JC virus, BK virus and simian virus 40, particularly in brain tumors and neuroblastoma, which belong to the most frequent malignancies in children. However, currently available data are controversial, possibly due to the different regional prevalence of the viruses and the detection techniques used. To elucidate the presence of these polyomaviruses in the indicated tumor entities and in childhood cancer in general, we have investigated a broad spectrum of pediatric malignancies, with particular emphasis on neuroblastoma from different geographic regions. More than 500 diagnostic specimens derived from 16 different pediatric cancer entities including solid tumors, leukemias and lymphomas were screened by highly sensitive and specific real-time quantitative PCR assays targeting important viral domains such as the large T-antigen, small T-antigen and virus protein 1. To ensure adequate power of the analysis, a minimum of 30 specimens were analyzed in each tumor entity. The vast majority of tumors investigated revealed negative findings, with only anecdotal presence of JC virus large/small T-antigen in individual cases of acute myeloid leukemia (1/30) and oligodendroglioma (1/30). Moreover, within a total of 111 neuroblastoma samples from different European countries, only a single case from Spain tested positive for BKV sequences. Our observations therefore reveal no evidence for the common presence of JC virus, BK virus or simian virus 40 in tumor tissue of pediatric malignancies and, in contrast to some earlier reports, provide no suggestion for an association between persistent infection with these viruses and childhood cancer.


Keywords

Polyomavirus, Large T antigen, Pediatric cancer, Brain tumor, Neuroblastoma


Abbreviations

ALL: Acute Lymphocytic Leukemia, AML: Acute Myeloid Leukemia, BKV: BK virus, CML: Chronic Myeloid Leukemia, HL: Hodgkin's lymphoma, HPyV: Human Polyomavirus, JCV: JV virus, MCPyV: Merkel Cell Polyomavirus, NCCR: Non-coding Control Region, NHL: Non-Hodgkin's lymphoma, RQ-PCR: Real-time Quantitative Polymerase Chain reaction, SV40: Simian virus 40, TAg: T-antigen, VP1: Virus Protein1.


Introduction

Human polyomaviruses (HPyV) belong to the family of small, non-enveloped DNA viruses. For several years, this family included only the human JC virus (JCV), which causes progressive multifocal leukoencephalopathy [1], and the human BK virus (BKV), causing mainly urinary tract infections [2]. Recent technological improvements permitted the identification of eight novel HPyV members in the last six years [3]. Most primary infections with the ubiquitous HPyV occur during the early childhood, usually without leading to serious clinical symptoms [4]. After primary exposure, the viral DNA can persist in individual cells by establishing a latent form of infection, and persistence of BKV and JCV can be detected in 75-90% of healthy individuals [5]. The possible role of BKV, JCV and the simian virus 40 (SV40) in human tumor formation has been a matter of debate for several decades [6,7] because these viruses display strong oncogenic potential after inoculation into rodents, with particular tropism to neural tissue [8]. The presence of BKV was documented in urothelial carcinoma, and the virus was suggested to play a contributory role in the pathogenesis of neuroblastoma [6,9,10]. The brain apparently serves as a sanctuary for the persistence of different viruses including JCV, and several studies reported the presence of viral sequences in various brain tumors [7,11,12]. As opposed to viral persistence as a putative source of oncogenic hits, the frequent detection of SV40 in brain tumors and other malignancies like Wilms'tumor, Ewing sarcoma, osteosarcoma or lymphoma was generally linked to the use of virus-contaminated polio vaccines several decades ago [13-16]. In contrast to studies describing the presence of BKV, JCV or SV40 in various tumors, other reports did not reveal any evidence for these viruses in brain tumors, other solid tumors or hematologic malignancies [17-22]. The conflicting data on the presence or absence of polyomavirus DNA in human malignancy might be, at least in part, attributable to regional differences in the occurrence of polyomaviruses or the technical approaches to virus detection providing different levels of sensitivity and specificity. One of the recently identified HPyV, the Merkel cell polyomavirus (MCPyV), has been under intensive investigation as a potential human tumor virus since its detection in patients with Merkel cell carcinoma, a rare type of skin cancer [23,24]. However, there are pronounced differences in DNA sequence to other HPyV, and the original cell type for MCPyV replication has not been elucidated so far.

With regard to the oncogenic potential of polyomaviruses, the main focus of attention centered on the early regulatory protein, the large T-antigen (large TAg). This protein is mainly located in the nucleus and displays binding sites for cellular proteins involved in growth regulation, such as the tumor suppressor proteins retinoblastoma protein, p53 and p300 [25,26]. Several studies have focused on the large TAg of SV40, which is closely related to that of the human polyomaviruses BKV and JCV, and reported an oncogenic capacity in rodents as well as the ability to transform human cells in culture [27-29]. A group studying BKV in neuroblastoma investigated the interaction of large TAg with p53 suggesting an inhibition of the antiproliferative effect of wild type p53 in this tumor [9]. The large TAg genes comprise nearly half of the entire viral genome and display an overlapping area at the 5'end coding for the small T-antigen (small TAg), which is known to contribute to the oncogenic capacity of HPyV in rodents [30]. The gene responsible for the oncogenic properties of MCPyV was also shown to be large TAg. Interestingly, in Merkel cell carcinoma only a truncated version of this gene has been detected, which is not compatible with viral replication [31].

The inconclusive data on the possible involvement of the polyomaviruses BKV, JCV and SV40 in the pathogenesis of human tumors, particularly of pediatric malignancies, prompted us to carry out the present study. We have investigated a large spectrum of pediatric malignant disorders including different solid tumors, leukemias, and lymphomas by highly sensitive real-time quantitative PCR (RQ-PCR) assays targeting viral genes demonstrated to be crucial for the oncogenic properties of BKV, JCV and SV40, with the aim to shed more light on the hitherto enigmatic potential role of these viruses in human neoplastic disorders.


Materials and Methods

Patients

Archived diagnostic specimens from pediatric patients with various types of solid tumors and leukemias including 337 fresh-frozen and 240 paraffin-embedded samples were collected for viral DNA screening. The fresh-frozen specimens tested were derived from patients treated at our clinical center, the St. Anna Children's Hospital, Vienna, Austria, and included all leukemia (n=120) and lymphoma (n=71) samples analyzed as well as Wilms' tumor (n=30), Ewing sarcoma (n=30), neuroblastoma (n=39), embryonal rhabdomyosarcoma (n=26) and osteosarcoma (n=21) samples, with informed consent. The leukemias investigated included diagnostic peripheral blood or bone marrow samples of the following entities: B-cell acute lymphocytic leukemia (B-ALL; n=30), T-cell acute lymphocytic leukemia (T-ALL; n=30), acute myeloid leukemia (AML; n=30) and chronic myeloid leukemia (CML; n=30). Lymph nodes from the time of diagnosis of Hodgkin's lymphoma (HL; n=33) and Non-Hodgkin's lymphoma (NHL; n=38, including both B-cell and T-cell NHL) were tested.

Additionally, paraffin-embedded diagnostic tumor tissue was kindly provided by the Dept. of Clinical Pathology, Medical University of Vienna, including alveolar rhabdomyosarcoma (n=9) and osteosarcoma (n=9). Three 10μm sections of the rhabdomyosarcoma and osteosarcoma specimens were cut from each block using fresh disposable microtome blades to prevent cross-contamination. Moreover, brain tumor specimens including ependymoma (n=30), glioblastoma (n=30), oligodendroglioma (n=30), astrocytoma (n=30), and medulloblastoma (n=30) were kindly provided by the Institute of Neurology, Medical University of Vienna (Table 1). The glioblastoma, oligodendroglioma and five of the ependymoma specimens were derived from patients beyond 18 years of age. Punch sections of about 1mm in diameter targeting regions with high density of tumor cells were excised from the paraffin-embedded brain tumor tissue. Furthermore, paraffin-embedded diagnostic neuroblastoma samples were obtained from other geographic regions including Belgium (Center for Medical Genetics, Ghent University Hospital; n=10), France (Centre Leon Berard, Unite d'Oncologie Moleculaire, Lyon; n=17), Germany (Center for Pediatrics, University of Freiburg; n=10), Portugal (National Institute de Saude, Lisbon; n=5), Romania (Hospital de Cioii Louis Turcanu, Pediatric Clinic III, Temesvar; n=15), and Spain (Department of Pathology, Medical School, University of Valencia; n=15) (Table 2).



Table 1: RQ-PCR analysis in tumor cells for BKV, JCV and SV40 View Table 1



Table 2: Testing for BKV DNA in neuroblastoma specimens from different European countries View Table 2


DNA extraction

Peripheral blood and bone marrow specimens from leukemia patients were subjected to DNA extraction by the QIAmp Blood DNA Mini Kit (QIAGEN, Hilden, Germany) according to the manufacturer's recommendations. DNA extraction from lymphoma samples and paraffin-embedded tissue was done by the QIAmp tissue DNA Mini Kit (QIAGEN, Hilden, Germany) according to the manufacturer's recommendations. In our earlier studies, the indicated kits were shown to facilitate efficient DNA isolation from a variety of viruses including HPyV [32]. In other solid tumor specimens, DNA extraction was performed by conventional tissue lysis using proteinase K at 56°C overnight, followed by DNA precipitation with 96% ethanol. The DNA yield and purity were determined by photometric analysis using the Spectrophotometer U-2000 (HITACHI, Japan).


RQ-PCR analysis

Primers and TaqMan® probes (Eurogentec) or minor groove binding probes (Life technologies) for RQ-PCR analysis of JCV, BKV and SV40 DNA target sequences were designed using the Primer Express software Version 2.0.0 (Life technologies). The primer/probe systems targeting virus protein 1 (VP1) and an overlapping region coding for the large TAg and small TAg genes were designed and optimized for uniform amplification protocols with an annealing temperature of 60°C (Table 3). For BKV analysis, additional primers and probe were designed for the non-coding control region (NCCR) to cover a greater proportion of the viral genome (Table 3).



Table 3: Primers and probes for RQ-PCR analysis of BKV, JCV and SV40 target sequences View Table 3


All reactions were set up in a total volume of 25μl containing the RQ-PCR Mastermix Plus (Eurogentec) and 6μl DNA template. The amplifications were carried out using the ABI Prism© 7700 or ABI Prism© 7900 Sequence Detector (Life technologies) with an initial denaturation at 95°C for 10 minutes, followed by 50 cycles consisting of denaturation at 95°C for 15 seconds and annealing plus extension at 60°C for 60 seconds. Strict precautions were undertaken to prevent exogenous contamination of the PCR assays. To reduce the risk of false-positive results due to contamination with PCR products, desoxythymidintriphosphat was partially replaced by desoxyuraciltriphosphat in the reaction mastermix, and a desoxyuraciltriphosphat glycosylase step was performed prior to each PCR reaction, as described previously [32]. Moreover, multiple negative controls lacking template DNA were included in each assay to monitor and exclude the possibility of contamination [32]. Plasmid standards of JCV (pJCV GS/B) [33] and SV40 (Simian virus 40 strain 777), were used for the establishment of standard curves and as positive controls in each PCR run as well as for spiking experiments in urine samples using defined viral copy numbers. The plasmids were kindly provided by K. Dörries, Institute of Virology und Immunobiology, University of Würzburg, Germany). BKV-positive samples from stem cell transplant recipients obtained from our diagnostic center (LabDia Labordiagnostik/Children's Cancer Research Institute, Vienna, Austria) including urine (n=12), peripheral blood (n=5), and cerebrospinal fluid (n=4) containing precisely quantified virus copy numbers ranging from 103 to 1010/ml have been exploited as positive controls and reference for the establishment of detection limits of the PCR detection systems described herein.


Specificity and sensitivity of RQ-PCR assays

Potential cross-reactivity of the primers and probes with related polyomaviruses or human DNA sequences has been excluded by testing against different polyomavirus strains and human genomic DNA. For all viruses tested, the detection limit of the indicated assays (Table 3) was 10-100 target copies per reaction, as determined by serially diluted standards and spiking experiments.


Quality control, virus copy number quantification, and dynamic range

Adequate quality and quantity of DNA isolated from tumor specimens was assessed by parallel RQ-PCR amplification of the human single-copy housekeeping gene beta2-microglobulin [32]. Results exceeding 5×103 control gene copies per reaction were obtained in all specimens from the entire range of tumor entities, medulloblastoma being the only exception, where lower control gene copy numbers were observed in 18/30 specimens investigated. For standardization of the quantitative virus detection assays, serial dilutions of plasmid standards quantified by spectrophotometric and fluorometric measurements were used as external references for the calculation of virus particle numbers. Standard curves with these serial dilutions were established to permit linear virus quantification across at least seven logs covering a range from 102 to 107 virus particles. The calculation of virus copy numbers per cell was based on the quantification of beta2-microglobulin gene copies in each specimen tested, and was generally expressed as virus copy number per 106 cells.


Statistics

The one-sided 95% confidence intervals of the proportion of virus-positive samples were calculated for each tumor entity. In the presence of negative test results for viral sequences in the tumor samples investigated, the analysis of ≥30 different specimens from each tumor entity provided a probability of 90% for the lack of correlation between the presence of virus and the respective tumor type.


Results

Testing for BKV, JCV and SV40 DNA sequences in diagnostic tumor samples

More than 500 specimens from 16 tumor entities outlined in Table 1 were screened for the presence of large TAg /small TAg and VP1 gene sequences from the polyoma viruses BKV, JCV and SV40. The selection of target genes was based on their documented importance for the oncogenic properties of these viruses in experimental animal models. Among the specimens tested, only two revealed positive findings, including one AML and one oligodendroglioma specimen, which displayed large TAg/small TAg signals of the JC virus (Table 1). Quantitative analysis of the viral signals indicated the presence of 103-104 virus copies per 106 tumor cells. None of the tumor specimens within this series revealed evidence for the presence of BKV or SV40 DNA. The rare occurrence of JCV sequences appears to reflect an accidental phenomenon which might be attributable to occasional persistence of the virus in the respective tissue following primary infection. Hence, despite the employment of highly sensitive and specific detection methods, our systematic screening covering a large spectrum of primarily pediatric malignancies does not support published evidence for the presence of these polyoma viruses in tumor tissue, including particularly brain tumors [7,11]. It is necessary to consider, however, that all patients included in this series were diagnosed and treated in Austria, thus leaving the question unanswered whether geographic differences in the occurrence of these viruses might play a role in their association with malignant disease.


Screening for BKV DNA in neuroblastoma specimens from different European countries

A study performed by Flaegstad et al. in Swedish patients reported a 100% incidence of BKV in a series of 18 neuroblastoma samples [9]. In contrast to these findings, our analysis of 39 Austrian patients did not reveal any evidence for BKV DNA sequences in the diagnostic tumor specimens. To address the possibility of regional differences, we have sought to obtain neuroblastoma samples from different European countries, and were successful in receiving diagnostic specimens from six additional countries including Belgium, France, Germany Portugal, Romania and Spain (Table 2). A total of 111 neuroblastomas, including the samples from Austria, were screened by RQ-PCR for BKV genes coding for the large T-antigen, small T-antigen, VP1 and the NCCR. Virtually all neuroblastoma samples investigated tested negative for the indicated viral genes, the only exception being a single sample from Spain which revealed signals for BKV large T-antigen, VP1 and NCCR genes, suggesting the probable presence of the entire viral genome (Table 2). The assessment of virus copy numbers indicated less than 104 virus copies per 106 cells. The anecdotal presence of BKV in less than 1% of the neuroblastoma patients analyzed by a highly sensitive and specific technique does not support the prominent association of BKV with neuroblastoma reported earlier [9]. However, our study cannot exclude a regional association of BKV with neuroblastoma which might be prevalent in Scandinavia. In order to firmly establish whether the frequent detection of BKV sequences in neuroblastoma reported in the indicated study indeed represents an intriguing epidemiological phenomenon, and was not attributable to other factors including technical issues, investigation of independent patient cohorts from the region of interest would be warranted.


Discussion

The lack of evidence for the presence of JCV, BKV and SV40 in the study presented may be related to various factors beyond regional differences. The considerable sequence similarity between polyomaviruses, which is in the range of 70%, raises the issue of cross-reactivity between detection assays for these viruses, and possibly other viral sequences contained in the human genome. Efficient isolation of viral DNA from clinical specimens is a prerequisite for reliable downstream analyses, and the extraction methods employed in the present study were shown to be appropriate [32]. Aliquots of the tumor DNA samples investigated had been used previously in PCR-based screening for adenoviruses, and the presence of low virus copy numbers was demonstrated in several instances, thus indicating adequate purification of amplifiable viral DNA [12]. Screening techniques used decades ago may have displayed insufficient specificity facilitating false-positive findings. The high level of specificity and sensitivity provided by the RQ-PCR approaches employed in the current study in the presence of appropriate controls should largely preclude incorrect results. Moreover, the implementation of appropriate measures preventing carryover contamination in PCR-based analysis has certainly improved over the past years [12,34,35]. Nevertheless, confirmation of PCR-positive findings by independent techniques, such as fluorescence in situ hybridization (FISH) to intracellular viral sequences, is certainly desirable to render any observations of PCR-based screening approaches more reliable [12].

In contrast to viruses such as the human T-lymphotropic virus 1, the differences in the endemic occurrence of polyoma viruses may be less pronounced. Nevertheless, the reported prevalence of BKV in the United Kingdom is >80%, in China >40%, and in Japan only 5%, and such differences could, at least in part, explain the disparity between reports on virus detection in tumor tissue [7,13,36,37]. A geographic impact therefore cannot be entirely excluded. This notion is exemplified by the lack of evidence for the presence of SV40 in our study, because the contaminated vaccine held responsible for the occurrence of SV40-related diseases apparently was never used in Austria [14,15]. It may be of interest in this regard that some of the studies reporting a high prevalence of SV40 in brain tumors are from Italy where the population was exposed to the SV40-contaminated polio vaccine [14,38]. However, epidemiological data from Italy do not show a particularly high prevalence of brain tumors. These occur at a considerably higher frequency in other parts of Europe including Scandinavia and Southeastern European countries where the contaminated vaccine was not used [39]. Recent studies based on systematic screening of brain tumors reported occasional occurrence of HPyV, but did not provide any evidence for an association between presence of the virus and tumor formation [20,40]. These results highlight the importance of functional studies to link detection of viral sequences in tumor tissue to the pathogenesis of the malignancy investigated. In this regard, the screening for the presence of viral DNA can only be regarded as a first step towards understanding the processes involved in viral oncogenesis.


Conclusion

The absence of viral sequences in virtually all tumor specimens included in the present study despite the use of a highly sensitive and specific screening approach does not support an implication of the polyomaviruses BKV, JCV or SV40 in brain tumors, neuroblastoma or other pediatric malignancies.


Acknowledgements

This study was performed with financial support from the Jubiläumsfonds of the National Bank of Austria (grant no. 11168). The authors wish to express their gratitude to colleagues from the Center for Medical Genetics, Ghent University Hospital, Belgium; Centre Leon Berard, Unite d'Oncologie Moleculaire, Lyon, France; Center for Pediatrics, University of Freiburg, Germany; National Institute de Saude, Lisabon, Portugal; Hospital de Cioii Louis Turcanu, Pediatric Clinic III, Temeswar, Romania; Department of Pathology, Medical School, University of Valencia, Valencia, Spain, for kindly providing their archived neuroblastoma samples for the present study.


Ethical Statement

For the human specimens informed consent is available.


References
  1. Padgett BL, Walker DL, ZuRhein GM, Eckroade RJ, Dessel BH (1971) Cultivation of papova-like virus from human brain with progressive multifocal leucoencephalopathy. Lancet 1: 1257-1260.

  2. Gardner SD, Field AM, Coleman DV, Hulme B (1971) New human papovavirus (B.K.) isolated from urine after renal transplantation. Lancet 1: 1253-1257.

  3. White MK, Gordon J, Khalili K (2013) The rapidly expanding family of human polyomaviruses: recent developments in understanding their life cycle and role in human pathology. PLoS Pathog 9: e1003206.

  4. Egli A, Infanti L, Dumoulin A, Buser A, Samaridis J, et al. (2009) Prevalence of polyomavirus BK and JC infection and replication in 400 healthy blood donors. J Infect Dis 199: 837-846.

  5. Doerries K (2006) Human polyomavirus JC and BK persistent infection. Adv Exp Med Biol 577: 102-116.

  6. De Mattei M, Martini F, Corallini A, Gerosa M, Scotlandi K, et al. (1995) High incidence of BK virus large-T-antigen-coding sequences in normal human tissues and tumors of different histotypes. Int J Cancer 61: 756-760.

  7. Del Valle L, Gordon J, Assimakopoulou M, Enam S, Geddes JF, et al. (2001) Detection of JC virus DNA sequences and expression of the viral regulatory protein T-antigen in tumors of the central nervous system. Cancer Res 61: 4287-4293.

  8. Walsh JW, Zimmer SG, Perdue ML (1982) Role of viruses in the induction of primary intracranial tumors. Neurosurgery 10: 643-662.

  9. Flaegstad T, Andresen PA, Johnsen JI, Asomani SK, Jørgensen GE, et al. (1999) A possible contributory role of BK virus infection in neuroblastoma development. Cancer Res 59: 1160-1163.

  10. Knöll A, Stoehr R, Jilg W, Hartmann A (2003) Low frequency of human polyomavirus BKV and JCV DNA in urothelial carcinomas of the renal pelvis and renal cell carcinomas. Oncol Rep 10: 487-491.

  11. Krynska B, Del Valle L, Croul S, Gordon J, Katsetos CD, et al. (1999) Detection of human neurotropic JC virus DNA sequence and expression of the viral oncogenic protein in pediatric medulloblastomas. Proc Natl Acad Sci U S A 96: 11519-11524.

  12. Kosulin K, Haberler C, Hainfellner JA, Amann G, Lang S, et al. (2007) Investigation of adenovirus occurrence in pediatric tumor entities. J Virol 81: 7629-7635.

  13. Huang H, Reis R, Yonekawa Y, Lopes JM, Kleihues P, et al. (1999) Identification in human brain tumors of DNA sequences specific for SV40 large T antigen. Brain Pathol 9: 33-42.

  14. Martini F, Iaccheri L, Lazzarin L, Carinci P, Corallini A, et al. (1996) SV40 early region and large T antigen in human brain tumors, peripheral blood cells, and sperm fluids from healthy individuals. Cancer Res 56: 4820-4825.

  15. Martini F, Lazzarin L, Iaccheri L, Vignocchi B, Finocchiaro G, et al. (2002) Different simian virus 40 genomic regions and sequences homologous with SV40 large T antigen in DNA of human brain and bone tumors and of leukocytes from blood donors. Cancer 94: 1037-1048.

  16. Vilchez RA, Madden CR, Kozinetz CA, Halvorson SJ, White ZS, et al. (2002) Association between simian virus 40 and non-Hodgkin lymphoma. Lancet 359: 817-823.

  17. Weggen S, Bayer TA, von Deimling A, Reifenberger G, von Schweinitz D, et al. (2000) Low frequency of SV40, JC and BK polyomavirus sequences in human medulloblastomas, meningiomas and ependymomas. Brain Pathol 10: 85-92.

  18. Hayashi H, Endo S, Suzuki S, Tanaka S, Sawa H, et al. (2001) JC virus large T protein transforms rodent cells but is not involved in human medulloblastoma. Neuropathology 21: 129-137.

  19. Herbarth B, Meissner H, Westphal M, Wegner M (1998) Absence of polyomavirus JC in glial brain tumors and glioma-derived cell lines. Glia 22: 415-420.

  20. Chiaravalli AM, Longhi E, Vigetti D, De Stefano FI, Deleonibus S, et al. (2013) Gastrointestinal cancers reactive for the PAb416 antibody against JCV/SV40 T-Ag lack JCV DNA sequences while showing a distinctive pathologic profile. J Clin Pathol 66: 44-49.

  21. Stolt A, Kjellin M, Sasnauskas K, Luostarinen T, Koskela P, et al. (2005) Maternal human polyomavirus infection and risk of neuroblastoma in the child. Int J Cancer 113: 393-396.

  22. Smith MA, Strickler HD, Granovsky M, Reaman G, Linet M, et al. (1999) Investigation of leukemia cells from children with common acute lymphoblastic leukemia for genomic sequences of the primate polyomaviruses JC virus, BK virus, and simian virus 40. Med Pediatr Oncol 33: 441-443.

  23. Rodig SJ, Cheng J, Wardzala J, DoRosario A, Scanlon JJ, et al. (2012) Improved detection suggests all Merkel cell carcinomas harbor Merkel polyomavirus. J Clin Invest 122: 4645-4653.

  24. Spurgeon ME, Lambert PF (2013) Merkel cell polyomavirus: a newly discovered human virus with oncogenic potential. Virology 435: 118-130.

  25. Barbanti-Brodano G, Martini F, De Mattei M, Lazzarin L, Corallini A, et al. (1998) BK and JC human polyomaviruses and simian virus 40: natural history of infection in humans, experimental oncogenicity, and association with human tumors. Adv Virus Res 50: 69-99.

  26. Waltari M, Sihto H, Kukko H, Koljonen V, Sankila R, et al. (2011) Association of Merkel cell polyomavirus infection with tumor p53, KIT, stem cell factor, PDGFR-alpha and survival in Merkel cell carcinoma. Int J Cancer 129: 619-628.

  27. Pipas JM (1992) Common and unique features of T antigens encoded by the polyomavirus group. J Virol 66: 3979-3985.

  28. Conzen SD, Cole CN (1995) The three transforming regions of SV40 T antigen are required for immortalization of primary mouse embryo fibroblasts. Oncogene 11: 2295-2302.

  29. Shay JW, Van Der Haegen BA, Ying Y, Wright WE (1993) The frequency of immortalization of human fibroblasts and mammary epithelial cells transfected with SV40 large T-antigen. Exp Cell Res 209: 45-52.

  30. Imperiale MJ (2007) Polyomaviridae. In: Knipe DM, Howley PM, editor. Fields´ Virology. 5th ed. Philadelphia: Lippincott Williams & Wilkins. pp. 2263-2298.

  31. Shuda M, Feng H, Kwun HJ, Rosen ST, Gjoerup O, et al. (2008) T antigen mutations are a human tumor-specific signature for Merkel cell polyomavirus. Proc Natl Acad Sci U S A 105: 16272-16277.

  32. Watzinger F, Suda M, Preuner S, Baumgartinger R, Ebner K, et al. (2004) Real-time quantitative PCR assays for detection and monitoring of pathogenic human viruses in immunosuppressed pediatric patients. J Clin Microbiol 42: 5189-5198.

  33. Eggers C, Stellbrink HJ, Buhk T, Dörries K (1999) Quantification of JC virus DNA in the cerebrospinal fluid of patients with human immunodeficiency virus-associated progressive multifocal leukoencephalopathy-a longitudinal study. J Infect Dis 180: 1690-1694.

  34. Lion T, Baumgartinger R, Watzinger F, Matthes-Martin S, Suda M, et al. (2003) Molecular monitoring of adenovirus in peripheral blood after allogeneic bone marrow transplantation permits early diagnosis of disseminated disease. Blood 102: 1114-1120.

  35. Lion T, Kosulin K, Landlinger C, Rauch M, Preuner S, et al. (2010) Monitoring of adenovirus load in stool by real-time PCR permits early detection of impending invasive infection in patients after allogeneic stem cell transplantation. Leukemia 24: 706-714.

  36. Gu ZY, Li Q, Si YL, Li X, Hao HJ, et al. (2003) Prevalence of BK virus and JC virus in peripheral blood leukocytes and normal arterial walls in healthy individuals in China. J Med Virol 70: 600-605.

  37. Knowles WA, Pipkin P, Andrews N, Vyse A, Minor P, et al. (2003) Population-based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40. J Med Virol 71: 115-123.

  38. Paracchini V, Garte S, Pedotti P, Poli F, Frison S, et al. (2005) Molecular identification of simian virus 40 infection in healthy Italian subjects by birth cohort. Mol Med 11: 48-51.

  39. Ferlay J SH, Bray F, Forman D, Mathers C and Parkin DM (2010) Cancer Incidence and Mortality Worldwide In: v2.0 G, editor. IARC CancerBase No 10: Lyon, France: International Agency for Research on Cancer.

  40. Rollison DE, Utaipat U, Ryschkewitsch C, Hou J, Goldthwaite P, et al. (2005) Investigation of human brain tumors for the presence of polyomavirus genome sequences by two independent laboratories. Int J Cancer 113: 769-774.

International Journal of Anesthetics and Anesthesiology (ISSN: 2377-4630)
International Journal of Blood Research and Disorders   (ISSN: 2469-5696)
International Journal of Brain Disorders and Treatment (ISSN: 2469-5866)
International Journal of Cancer and Clinical Research (ISSN: 2378-3419)
International Journal of Clinical Cardiology (ISSN: 2469-5696)
Journal of Clinical Gastroenterology and Treatment (ISSN: 2469-584X)
Clinical Medical Reviews and Case Reports (ISSN: 2378-3656)
Journal of Dermatology Research and Therapy (ISSN: 2469-5750)
International Journal of Diabetes and Clinical Research (ISSN: 2377-3634)
Journal of Family Medicine and Disease Prevention (ISSN: 2469-5793)
Journal of Genetics and Genome Research (ISSN: 2378-3648)
Journal of Geriatric Medicine and Gerontology (ISSN: 2469-5858)
International Journal of Immunology and Immunotherapy (ISSN: 2378-3672)
International Journal of Medical Nano Research (ISSN: 2378-3664)
International Journal of Neurology and Neurotherapy (ISSN: 2378-3001)
International Archives of Nursing and Health Care (ISSN: 2469-5823)
International Journal of Ophthalmology and Clinical Research (ISSN: 2378-346X)
International Journal of Oral and Dental Health (ISSN: 2469-5734)
International Journal of Pathology and Clinical Research (ISSN: 2469-5807)
International Journal of Pediatric Research (ISSN: 2469-5769)
International Journal of Respiratory and Pulmonary Medicine (ISSN: 2378-3516)
Journal of Rheumatic Diseases and Treatment (ISSN: 2469-5726)
International Journal of Sports and Exercise Medicine (ISSN: 2469-5718)
International Journal of Stem Cell Research & Therapy (ISSN: 2469-570X)
International Journal of Surgery Research and Practice (ISSN: 2378-3397)
Trauma Cases and Reviews (ISSN: 2469-5777)
International Archives of Urology and Complications (ISSN: 2469-5742)
International Journal of Virology and AIDS (ISSN: 2469-567X)
More Journals

Contact Us

ClinMed International Library | Science Resource Online LLC
3511 Silverside Road, Suite 105, Wilmington, DE 19810, USA
Email: contact@clinmedlib.org
 

Feedback

Get Email alerts
 
Creative Commons License
Open Access
by ClinMed International Library is licensed under a Creative Commons Attribution 4.0 International License based on a work at https://clinmedjournals.org/.
Copyright © 2017 ClinMed International Library. All Rights Reserved.